Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Foundation Medicine
With
Johns Hopkins University
Oncology Consultants
Comprehensive Blood and Cancer Center
Illinois CancerCare
Sanford Health
Eastchester Center for Cancer Care
Rutgers Cancer Institute of New Jersey
Cone Health
Nebraska Cancer Specialists
University of California, Davis
University of Chicago
Northeast Georgia Medical Center
Hematology Oncology Associates of Fredericksburg
Memorial Sloan Kettering Cancer Center
Oncology Hematology Care, Inc
Montefiore Medical Center
Quincy Medical Group
Prisma Health-Upstate
Mary Crowley Cancer Research Center
Texas Health
University of California, San Diego
Avera Cancer Institute
The purpose of this study is to assess whether a new ctDNA assay developed by Foundation Medicine is able to detect genomic alterations in peripheral blood that are consistent with the genomic alterations detected in a patient's matched primary and/or metastatic tumor biopsy sample analyzed by the FoundationOne® test. Study sites will provide matched solid tumor and peripheral blood samples of cancer patients to FMI for the purpose of testing the concordance of the FMI ctDNA assay to the FoundationOne® test. Participation in this study is part of a broader 2000 patient study to determine which tumor types are most readily measured via ctDNA profiling, and to learn of the similarity between the alterations found in a patient's tumor biopsy and the ctDNA from their blood.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have had a solid tumor biopsy isolated for analysis by FoundationOne under their standard clinical care
You may not be if
Tumor specimens where no cancer representative of the diagnosis is found in submitted tissue
Tumor specimens where insufficient DNA (\<50 ng) is provided to run the FoundationOne test.
Tumor specimens with ≤20% tumor nuclei (all specimens).
